XL184 is a new drug that is being developed to treat metastatic prostate cancer in the bone. XL184 works by blocking the “angiogenesis,” or the growth of new blood vessels, to the tumor.
Dr. Barken reviews briefly information from the article published in Current Opinions in Urology, 2011. Dr. Vogelzang brings his remarks about XL-184 ( Recent ASCO meeting)
Ongoing study :Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer. Location:
| United States, Massachusetts | |
| Massachusetts General Hospital | Recruiting |
| Boston, Massachusetts, United States, 02114 | |
| Contact: Matthew R Smith, MD, PhD 617-724-5257 | |
For more information, click Here: http://clinicaltrials.gov/ct2/show/NCT01347788?term=xl+184+and+prostate&rank=1
A new study about to start recruiting: Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone.
Location:
| Principal Investigator: | David C. Smith, M.D. | University of Michigan |
More info: Please click here: http://clinicaltrials.gov/ct2/show/NCT01428219?term=xl-184+%2C+prostate+cancer&rank=1
You must log in to post a comment.